Skip to main content

Table 4 Sensitivity analysis

From: Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis

No.Study that leaveOR rateCR rateRR
Relative rate (95% CI)I2 (%)p-valueRelative rate (95% CI)I2 (%)p-valueRelative rate (95% CI)I2 (%)p-value
A4Berentsen (2006)1.09 (1.00, 1.19)34.440.141.15 (0.98, 1.35)48.370.05   
A12Michel (2009)1.20 (1.02, 1.40)75.150.001.19 (0.99, 1.43)56.560.020.96 (0.55, 1.71)48.420.07
A18Birgens (2013)1.20 (1.03, 1.39)74.940.001.18 (0.99, 1.41)55.560.02   
A20Barcellini (2014)1.22 (1.02, 1.45)75.070.001.21 (0.98, 1.48)56.950.020.99 (0.54, 1.83)46.250.08
A21Roumier (2014)1.18 (1.01, 1.37)74.800.001.12 (0.95, 1.33)47.140.060.90 (0.47, 1.73)48.420.07
A23Fu (2016)1.22 (1.02, 1.46)75.170.001.16 (0.97, 1.40)56.230.020.88 (0.49, 1.56)46.940.08
A27Michel (2017)1.15 (1.00, 1.32)71.680.001.13 (0.96, 1.34)48.940.050.96 (0.56, 1.65)47.720.07
M7Froissart (2012)1.16 (0.99, 1.37)71.240.001.15 (0.93, 1.41)40.600.100.83 (0.49, 1.56)39.830.13
M9Hie (2014)1.19 (1.02, 1.38)75.200.001.18 (0.98, 1.44)57.310.021.09 (0.74, 1.60)0.000.47
M10Khandelwal (2014)1.23 (1.04, 1.46)70.040.001.24 (1.03, 1.49)25.520.220.83 (0.50, 1.35)32.180.18